Showing 5121-5130 of 20470 results for "".
- FDA Priority Review for Vyvgart in Seronegative MGhttps://reachmd.com/news/fda-priority-review-vyvgart-seronegative-mg/2485305/The FDA has accepted a supplemental Biologics License Application for Vyvgart (efgartigimod alfa-fcab), seeking an expanded indication for adults with AChR-Ab seronegative general
- Hemoglobin Levels Predict Cyclosporin A Exposure in Pediatric Renal Transplant Patientshttps://reachmd.com/news/hemoglobin-cyclosporin-a-pediatric-renal-transplant/2485289/A population pharmacokinetic analysis of pediatric renal transplant recipients found that hemoglobin strongly influences exposure to cyclosporin A, identifying it as a reproducible covariate that
- Study: Photodynamic Therapy Usage Shifts With Season, Geographyhttps://reachmd.com/news/study-photodynamic-therapy-usage-shifts-with-season-geography/2485308/Seasonal and geographic variation influences the use of photodynamic therapy (PDT) for actinic keratoses (AKs), according to a large cross-sectional study. Reasearchers analyzed over 79 million procedural claims from 2015 to 202
- Optimizing Perioperative Risk: Understanding the Role of Preoperative Stress in Surgical Outcomeshttps://reachmd.com/news/optimizing-perioperative-risk-understanding-the-role-of-preoperative-stress-in-surgical-outcomes/2485267/Higher preoperative stressor counts predict longer hospital stays, greater postoperative pain, and increased delirium risk in older adults — highlighting the potential value of pragmatic preoperative screening to identify higher-risk patients. In a cohort analysis of
- Unlocking the Mystery: Non-Coding RNA Mutations in Retinitis Pigmentosahttps://reachmd.com/news/unlocking-the-mystery-non-coding-rna-mutations-in-retinitis-pigmentosa/2485268/A research team has identified mutations in non-coding RNA genes as a cause of retinitis pigmentosa, expanding the diagnostic landscape for in
- Stewardship and Challenges: Antifungal Use in NICUshttps://reachmd.com/news/stewardship-and-challenges-antifungal-use-in-nicus/2485281/Rising empirical antifungal use in NICUs—driven by diagnostic gaps and inconsistent neonatal dosing—has accelerated resistant Candida emergence and exposed vulnerable neon
- FDA Approves Once-Daily Oral Semaglutidehttps://reachmd.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- New Peptide Serum Complements In-Office Aesthetic Treatmentshttps://reachmd.com/news/new-peptide-serum-complements-in-office-aesthetic-treatments/2485257/ZO® Skin Health has introduced the Peptide Facial Refining Concentrate, an advanced at-home serum formulated to complement professional aesthetic procedures and enhance overall facial rejuvenation. The launch adds to the company’s physician-dispensed portfolio with
- Envudeucitinib Phase 3 ONWARD Trial Results Unveiledhttps://reachmd.com/news/envudeucitinib-phase-3-trial-results/2485240/Alumis Inc. has announced positive topline results from its Phase 3
- The Gut-Liver Axis: Phytochemicals as Modulators of Cardiovascular Healthhttps://reachmd.com/news/the-gut-liver-axis-phytochemicals-as-modulators-of-cardiovascular-health/2485217/A recent synthesis shows dietary phytochemicals modulate the gut–liver axis in ways directly relevant to cardiovascular risk, targeting microbiota composition, intestinal barrier integrity, and b